FIELD: medicine.
SUBSTANCE: in new compounds of the formula R1 represents hydrogen, halogen; R2 represents C3-4 alkyl, or C3-6 cycloalkyl; R3 represents hydrogen or C1-3 alkyl; R4 represents -S(O)2R6, or -C(O)R7; R5 represents hydrogen, C1-3 alkyl, C2-3 alkyl substituted with -OH or C1-3alkoxy, or -CH2-pyridyl; R6 represents C1-3 alkyl, or R5 and R6 taken together form a C3-4 alkylenyl; and R7 represents hydrogen, C1-3 alkyl or pyridyl; or their pharmaceutically acceptable salts or solvates or stereoisomers. The invention also refers to pharmaceutical composition, to compounds application, to method for treating mammals, to method for treating disorders of reduced motor activity of gastrointestinal tract in a mammal, to method for obtaining compounds according to any of Clauses 1-12, to method for obtaining compounds of formula (I'), as well as to compounds of formula (III).
EFFECT: obtaining new biologically active compounds having activity as 5-NT4 receptors.
24 cl, 29 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
5-HT RECEPTOR AGONIST COMPOUNDS FOR TREATING COGNITIVE DISORDERS | 2010 |
|
RU2569056C2 |
INDAZOLE-CARBOXAMIDE COMPOUNDS | 2005 |
|
RU2404179C2 |
COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
BETA-LACTAMASE INHIBITORS | 2009 |
|
RU2445314C9 |
NOVEL BETA-LACTAMASE INHIBITOR AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2693898C2 |
NEW β-LACTAMASE INHIBITOR AND A METHOD OF ITS PRODUCTION | 2019 |
|
RU2800050C2 |
CONDENSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | 2007 |
|
RU2443698C2 |
CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
PHARMACEUTICAL COMPOUNDS | 2019 |
|
RU2821941C2 |
DIPEPTIDYL PEPTIDASE-IV INHIBITORS | 2010 |
|
RU2574410C2 |
Authors
Dates
2010-07-10—Published
2005-04-06—Filed